Revance Therapeutics reported $85.21M in Stock for its fiscal quarter ending in September of 2024.



Stock Change Date
AbbVie USD 4.95B 13M Dec/2025
ALKERMES USD 336.7M 140.08M Mar/2026
Bristol-Myers Squibb USD 2.76B 66M Mar/2026
Cara Therapeutics USD 900K 0 Mar/2025
Coherus Biosciences USD 3.17M 1.12M Dec/2025
Eli Lilly USD 14.53B 785M Mar/2026
J&J USD 14.58B 392M Mar/2026
Merck USD 6.48B 179M Mar/2026
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
P&G USD 7.85B 36M Mar/2026
Pacira USD 150.37M 2.49M Mar/2026
Supernus Pharmaceuticals USD 110.77M 1.71M Mar/2026